Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: A single-center, real-life experience

Haematologica

Volumn 97, Issue 4, 2012, Pages 560-567

  Girmenia, Corrado ^a   Frustaci, Anna Maria ^a   Gentile, Giuseppe ^a   Minotti, Clara ^a   Cartoni, Claudio ^a   Capria, Saveria ^a   Trisolini, Silvia Maria ^a   Matturro, Angela ^a   Loglisci, Giuseppina ^a   Latagliata, Roberto ^a   Breccia, Massimo ^a   Meloni, Giovanna ^a   Alimena, Giuliana ^a   Foà, Robin ^a   Micozzi, Alessandra ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukemia; Antifungal prophylaxis; Aspergillosis; Invasive fungal diseases; Posaconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITALIZATION COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HOSPITALIZATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84859476239     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.053058     Document Type: Article

References (35)

1. Anderlini P, Luna M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996;10 (4):600-608.
2. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068-1075.
3. Pagano L, Caira M, Picardi M, Candoni A, Melillo L, Fianchi L, et al. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report. Clin Infect Dis. 2007;44(11):1524-1525.
4. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica. 2010;95(4):644-650.
5. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis. 2008;47(12):1507-1512.
6. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stemcell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34): 5471-5489
7. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359.
8. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360.
9. Meunier F, Lukan C. The First European Conference on Infections in Leukaemia- ECIL1: a current perspective. Eur J Cancer. 2008;44(15):2112-2117.
10. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, et al. Primary rophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94 (1):113-122.
11. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis--has the principle been proven? N Engl J Med. 2007;356(4):409-411.
12. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28(4):667-674.
13. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, et al. Use of glycol sylated recombinant human G-CSF (leno grastim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106 (1):27-34.
14. Jehn U, Suciu S, Thomas X, Lefrère F, Muus P, Berneman Z, et al. Non-in fusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia. 2006; 20(10):1723-1730;
15. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27(32):5397-5403.
16. Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L, et al. Randomized trial of two schedules of low-dose gemtuzumabozogamicin as induction mono therapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol. 2010;149(3):376-382.
17. Sanz M, Burnett A, Lo-Coco F, Löwenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol. 2009;21 (6):594-600.
18. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-41821.
19. Gianino MM, Vallino A, Anselmo E, Minniti D, Abbona F, Mineccia C, Silvaplana P Zotti CM. Una metodologia di determinazione dei costi delle infezioni nosocomiali. Ann Ig 2007;19(4):381-392.
20. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis. 2008; 47(12):1507-1512.
21. Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65(7):1466-1471.
22. Hahn J, Stifel F, Reichle A, Holler E, Andreesen R. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit. Mycoses. 2011;54(Suppl 1):12-16.
23. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring fortriazoles. Curr Opin Infect Dis. 2008;21(6):580-586.
24. Girmenia C. New generation azole antifungalsin clinical investigation. Expert Opin Investig Drugs. 2009;18(9):1279-1295.
25. Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother. 2010;65(3):410-416.
26. Müller C, Arndt M, Queckenberg C, Cornely OA, Theisohn M. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses. 2006;49 (Suppl 1):17-22.
27. Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard JP, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother. 2009;53(12):5224-5229.
28. Thompson GR, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother. 2009;53(5):2223-2234.
29. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12): 1762-1769.
30. Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neu tropenia. Am J Health Syst Pharm. 2008; 65 (23):2237-2243.
31. Al-Badriyeh D, Slavin M, Liew D, Thursky K, Downey M, Grigg A, et al. Pharmaco economic evaluation of voriconazoleversus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J Antimicrob Chemother. 2010;65(5):1052-1061.
32. O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health. 2009;12(5):666-673.
33. de la Cámara RD, Jarque I, Sanz MA, Grau S, Casado MA, Sabater FJ, et al. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant. 2010;45 (5):925-932.
34. Jansen JP, O'Sullivan AK, Lugtenburg E, Span LF, Janssen JJ, Stam WB. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Ann Hematol. 2010;89(9):919-26.
35. Lyseng-Williamson KA. Posaconazole: apharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics. 2011;29 (3):251-268.